Presentations—8th Annual Fellows Forum in Breast Oncology - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations—8th Annual Fellows Forum in Breast Oncology

Engaging the Next Generation of Oncology Leaders

Not a member of My prIME? Join now for instant access.

Explore downloadable slides of expert case presentations on ER-, BRCA- and HER2-positive, and triple negative breast cancer presented at the 8th Annual Fellows Forum in Breast Oncology in Chicago. Each presentation includes a detailed case review followed by a discussion of the evidence base that supports the selected management approach.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Jun 7, 2019

Expiration Date

Jun 7, 2020

Featured Experts

  • Tal Sella, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
  • Eric P. Winer, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

Case #1 – ER-positive metastatic breast cancer

Featured Experts

  • Evie Hobbs, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
  • Jennifer Litton, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, Unites States

Featured Topic

Case #2 – BRCA-positive breast cancer

Featured Experts

  • Rebecca Deboer, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
  • Hope S. Rugo, MD, FASCO, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Featured Topic

Case #3 – New approaches to HER2-positive early breast cancer

Featured Experts

  • Giuseppe Curigliano, MD, PhD, European Institute of Oncology, University of Milan, Milan, Italy
  • Antonio Marra, MD, European Institute of Oncology, Milan, Italy

Featured Topic

Case #4 – Triple-negative metastatic breast cancer – Is it time to embrace immunotherapy?

This educational activity is specifically designed for physicians in training in medical oncology who are interested in breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe recent findings from ongoing clinical trials of new therapeutic options for breast cancer
  • Identify unmet needs in breast cancer research and treatment
  • Select optimal therapies for individual patients with breast cancer from among the available and emerging strategies

This educational activity is supported by a grant from Breast Cancer Research Foundation.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by Postgraduate Institute for Medicine and prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Curigliano has disclosed consulting fees from Daiichi Sankyo, Pfizer, Roche, and Seattle Genetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Deboer has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Hobbs has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Litton has disclosed contracted research for AstraZeneca, EMD-Serono, Genentech, and Pfizer. She also disclosed consulting fees (with fees refused) for advisory boards for AstraZeneca and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Marra has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Norton has disclosed consulting fees for participation in a Sermonix Oncology and a Context Therapeutics Ad Board Meeting. He also disclosed consulting fees received from Martell Diagnostics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Piccart has disclosed consulting fees from AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, Merk Sharpe and Dohme, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche PharmaMar, and Seattle Genetics. She disclosed scientific board membership with Oncolytics and Radius. She also disclosed research grants to her institution from AstraZeneca, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Radius, Roche-Genentech, Servier, and Synthon. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Reis-Filho has disclosed consulting fees from Belgian Volition, Genentech, Goldman Sachs, Grail, Invicro, Novartis, Paige.AI, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rugo has disclosed contracted research (funding to UC regents) for Eisai, Daiichi, Genentech, Immunomedics, Lilly, Merck, Novartis, OBI, Odonate, Pfizer, Seattle Genetics, and Macrogenics. She disclosed travel support from Amgen, Daiichi, Merck, Mylan, Pfizer, and Puma. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Sella has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Winer has disclosed consulting fees from Carrick Therapeutics, Genentech, GlaxoSmithKline, LEAP (SAB), Lilly, and Seattle Genetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Lisa Brauer, PhD (scientific content manager) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.